Every immunity shortlist puts chaga near the top and turkey tail somewhere in the middle. Sorted by what has actually been measured in people, that order comes close to reversing. One species here has five-year survival data behind it. Another has a trial in ordinary healthy adults eating ordinary amounts of food. Chaga, the mushroom this category sells hardest, has neither.
Trametes Versicolor has the strongest human immune evidence, but it comes from PSK — a purified pharmaceutical given alongside chemotherapy, where five-year survival reached 73.0% against 60.0% on chemotherapy alone (Nakazato 1994, n=262). Shiitake is the only species tested at food doses in healthy adults, raising γδ-T cell proliferation 60% over four weeks (Dai 2015, n=52). Chaga has no published randomised human trial and no established dose. And maitake's dose–response for immune markers proved non-monotonic: higher doses raised some parameters and depressed others (Deng 2009, p < 0.0005).
What follows is ranked by what has been measured in people, not by what sells. That produces some uncomfortable results for a shop that stocks all of these, and where our own products can't reach a trial dose, this article says so.
Which Mushroom Has the Strongest Human Immune Evidence?
Trametes Versicolor, by a wide margin. The 1994 Lancet trial randomised 262 patients who had undergone curative gastrectomy to standard adjuvant chemotherapy alone, or the same chemotherapy plus PSK — a protein-bound polysaccharide extracted from Trametes. Five-year survival was 73.0% against 60.0% (p = 0.044), and five-year disease-free survival 70.7% against 59.4% (p = 0.047).
Those are hard endpoints. Nobody else in this category has anything comparable — not a biomarker, not a questionnaire, but survival, followed for a minimum of five years across 46 Japanese institutions.
So Why Doesn't That Result Transfer to Turkey Tail Tea?
Because PSK isn't turkey tail. It's a purified protein-bound polysaccharide manufactured to a pharmaceutical specification, approved in Japan since 1977, and given at 3 grams a day for one to three years under oncology supervision. The organism is the same. The material in the trial is not the material in your cup.
We keep that distinction throughout. The schedule shape from the PSK trials may be informative; the dose is not transferable. Our turkey tail dosage guide works through why quoting the clinical figure on a consumer label overstates delivered polysaccharide several-fold.
What Has Been Tested in Ordinary Healthy People?
Shiitake, and only shiitake, at an amount you could reach with dinner. Fifty-two healthy adults aged 21 to 41 ate either 5 or 10 grams of whole dried shiitake daily for four weeks. Ex vivo γδ-T cell proliferation rose 60% (p < 0.0001), NK-T cell proliferation doubled (p < 0.0001), secretory IgA in saliva increased, and serum CRP fell.
Why does a 52-person study matter more than its size suggests? Because every other trial on this page recruited cancer patients. Dai's recruited people with nothing wrong with them, fed them food rather than an extract, and still moved cell-level immune measures.
One honest caveat, and it applies to the whole section: those are laboratory measures of how immune cells behave, not counts of illnesses avoided. No trial has shown that shiitake makes you catch fewer colds.
What Happened When Someone Pushed the Dose?
They ran out of study before they ran out of tolerance. A phase I escalation gave women recovering from breast-cancer radiotherapy 3, 6 or 9 grams a day of a Trametes preparation in divided doses for six weeks, three participants per cohort. Eleven were recruited, nine completed, and no maximum tolerated dose was reached at 9 grams.
Nine adverse events were reported across the whole study: seven mild, one moderate, one severe. Lymphocyte counts trended up at 6 and 9 grams and natural killer functional activity at 6 grams, with dose-related rises in CD8+ T cells and CD19+ B cells — but not in CD4+ T cells or CD16+56+ NK cells. It's small and uncontrolled, and it's still the only dose-ranging human safety data the category has.
Does More Beta-Glucan Mean More Immune Support?
No — and the one study that tested the question properly found the opposite of a straight line. Deng's 2009 phase I/II trial gave 34 postmenopausal breast cancer patients a maitake polysaccharide extract at 0.1, 0.5, 1.5, 3 or 5 mg/kg twice daily for three weeks. The association between maitake and immune function was statistically significant (p < 0.0005), and increasing doses raised some immunological parameters while depressing others.
The authors' own phrasing is worth preserving: the dose–response curves for many endpoints were non-monotonic, with intermediate doses producing either immune-enhancing or immune-suppressant effects compared with both high and low doses.
Now read that against the front of any immune mushroom bottle. The number printed there is a beta-glucan percentage, and the promise it implies is linear. The only human dose–response study in the category says the direction of effect at a given dose isn't predictable, which makes that number a weak guide to anything. Our label guide covers a second, independent reason the same percentage is unreliable.
Where Does Chaga Actually Sit?
Near the bottom, which will surprise anyone who has shopped this category. Chaga has no published randomised controlled trial in humans and no established dose. Its evidence base is in vitro and animal work plus a small case series — genuinely interesting mechanistic material, and not the same thing as a trial.
We sell chaga, and it sells well. The antioxidant framing it's marketed on rests largely on ORAC values, a measure the USDA removed from its own database because it didn't predict anything in the body. Chaga also carries the one cumulative-dose hazard in this category, an oxalate load with three published nephropathy cases behind it; our chaga safety article covers all three.
What About Reishi, Cordyceps and Tremella?
Reishi has human immune data, but in a sick population and without a clinical outcome. Gao's 2003 study gave 34 advanced-stage cancer patients 1,800 mg of a Ganoderma polysaccharide extract three times daily for 12 weeks, comparing cytokines, T-cell subsets, mitogen response and NK activity against baseline. It's an immunological before-and-after, not a controlled trial with an endpoint.
Cordyceps' human trials are about exercise capacity, not immunity; its immune reputation runs on cell and animal work, which our cordyceps and immunity article sets out. Tremella sits in the same position — a well-described polysaccharide mechanism and no immune trial in people, per our tremella polysaccharides article.
The Ranking, by Evidence
| Mushroom | Best human evidence | Tier |
|---|---|---|
| Trametes Versicolor | Five-year survival as adjuvant PSK; 9 g/day tolerated in a phase I | Strongest — but for a drug, not the tea |
| Shiitake | Food-dose trial in healthy adults; γδ-T +60%, NK-T doubled | Best evidence for how people actually use it |
| Maitake | Phase I/II dose escalation; effects real but non-monotonic | Informative, and a warning |
| Reishi | Immune parameters before-and-after in advanced cancer | Uncontrolled, sick population |
| Cordyceps militaris | Exercise endpoints only; no human immune trial | Extrapolation |
| Tremella | Mechanism only; no human immune trial | Speculative |
| Chaga | No randomised human trial; no established dose | Marketed far ahead of its evidence |
Why "Immune Support" Isn't Really an Endpoint
Here's the problem sitting underneath all of it. None of these trials measured whether anyone got ill less often. They measured cell proliferation, receptor expression, cytokine patterns, salivary antibody and CRP — and, in the oncology studies, survival.
A stronger γδ-T cell response in a culture dish is a reasonable thing to want. It isn't the same claim as "you'll catch fewer colds this winter", and the distance between those two statements is where most immunity marketing lives. No EU regulator will let a supplement make the second claim, which is precisely why the first one gets printed instead.
That gap also explains the ranking's shape. The species with real clinical endpoints got them inside cancer trials, because oncology is where anyone was willing to fund a five-year follow-up. Nobody has run the winter-cold study in healthy adults, so nobody can honestly tell you who wins it.
Who Should Be Careful Here
Anyone taking immunosuppressants, and anyone managing an autoimmune condition. Three of these species are stacked together in our own Forest Power Blend, and immunomodulation isn't a benign property when your immune system is already aimed the wrong way.
The Deng result makes that caution stronger, not weaker. "We can't predict the direction at your dose" is a poor thing to hear when the disease is your own immune system. Read our autoimmune article and the medication interactions guide before starting anything on this page.
How Would You Actually Pick One?
- Decide whether you want the best-evidenced species or the best-evidenced use. Those give different answers: Trametes for the first, shiitake for the second.
- Pick one. Stacking three immunomodulators means you can't attribute anything, good or bad, to any of them.
- Match a trial dose if one exists. Shiitake's is 5–10 grams of dried mushroom a day — food-scale, and cheaper than capsules.
- Give it four weeks minimum, which is what Dai's trial ran. Judging at day five tells you nothing.
- Don't expect to feel it. These trials moved laboratory measures, not sensations, so decide in advance what would count as a result for you.
Frequently Asked Questions
What is the best mushroom for immunity?
It depends which question you're asking. Trametes Versicolor has the strongest evidence — five-year survival of 73.0% against 60.0% as adjuvant PSK — but that was a purified pharmaceutical. For the way people actually use mushrooms, shiitake is the only species with a food-dose trial in healthy adults.
Is chaga good for the immune system?
There's no randomised human trial to answer that. Chaga's immune evidence is in vitro and animal work plus a small case series, and no dose has been established. It also carries a cumulative oxalate risk, with three published cases of kidney injury after months of gram-scale use.
Does a higher beta-glucan percentage mean better immune support?
Not reliably. The only human dose–response study in the category found the relationship non-monotonic (p < 0.0005): rising doses raised some immune parameters and depressed others. A higher number on the label doesn't predict a bigger effect, or even the direction of one.
How long before an immune mushroom does anything?
Dai's shiitake trial measured at four weeks; the Trametes phase I ran six; the reishi study ran twelve. Four weeks is the shortest interval anything has been detected over, so treat that as the floor for a self-test rather than a promise.
Can I take these if I have an autoimmune condition?
Ask your doctor first. No trial of any functional mushroom has been run in an autoimmune population, and the single dose–response study found the direction of immune effect unpredictable at a given dose. That uncertainty is the specific problem for anyone whose immune system is already overactive.
Shop Immune Support
Dried shiitake (50 g €39, 100 g €69) is the only product here that reaches a trial dose as food, at 5–10 g a day. Dried Trametes Versicolor (100 g €29, 300 g €69, 500 g €89) and Trametes tincture (50 ml €49, 100 ml €79) are the species with the strongest trial record, with the PSK caveat above. Chaga chunks (100 g €25, 300 g €39, 1 kg €59) are the cheapest way to drink chaga and lower the oxalate load than swallowed powder. The immunity collection holds the full range. Free shipping on orders over €50.
Related Articles
- Trametes Versicolor: PSK, PSP and Immune Modulation
- Shiitake, Lentinan and Immune Priming
- Maitake Immune Support and D-Fraction
- Chaga, Immune Modulation and NK Cells
- Mushrooms and Autoimmune Conditions
- Mushroom Blend vs Single Species
- Beta-Glucan vs Polysaccharide on Labels
Sources
- Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet. 1994;343(8906):1122-1126. PubMed 7910230
- Dai X, Stanilka JM, Rowe CA, et al. Consuming Lentinula edodes (shiitake) mushrooms daily improves human immunity: a randomized dietary intervention in healthy young adults. J Am Coll Nutr. 2015;34(6):478-487. PubMed 25866155
- Torkelson CJ, Sweet E, Martzen MR, et al. Phase 1 clinical trial of Trametes versicolor in women with breast cancer. ISRN Oncol. 2012;2012:251632. PubMed 22701186
- Deng G, Lin H, Seidman A, et al. A phase I/II trial of a polysaccharide extract from Grifola frondosa (maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol. 2009;135(9):1215-1221. PubMed 19253021
- Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003;32(3):201-215. PubMed 12916709